Dehydroepiandrosterone as a regulator of immune cell function

Journal of Steroid Biochemistry and Molecular Biology

Volumn 120, Issue 2-3, 2010, Pages 127-136

  Hazeldine, Jon ^a   Arlt, Wiebke ^a   Lord, Janet M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Ageing; DHEA; Immunity

Indexed keywords

ADJUVANT; ANDROGEN; ANDROSTENEDIOL; ANDROSTENETRIOL; PLACEBO; PRASTERONE; UNCLASSIFIED DRUG;

ACNE; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; CLINICAL TRIAL; COXSACKIE VIRUS INFECTION; CROHN DISEASE; ENTERITIS; GERIATRIC DISORDER; HIRSUTISM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; NONHUMAN; RHEUMATOID ARTHRITIS; RODENT; STEROIDOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; VACCINATION;

AGING; ANIMALS; DEHYDROEPIANDROSTERONE; HUMANS; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOID TISSUE;

RODENTIA;

EID: 77952958199     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.12.016     Document Type: Article

References (128)

1. Endoh A., Kristiansen S.-B., Casson P.-R., Buster J.-E., Hornsby P.-J. The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulphate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase. J. Clin. Endocrinol. Metab. 1996, 81(10):3558-3565.
2. Longcope C. The metabolism of DHEA, dehydroepiandrosterone (DHEA) and aging. Ann. NY. Acad. Sci. 1995, 774:143-148.
3. Migeon C.-J., Keller A.-R., Lawrence B., Shepard T.-H. Dehydroepiandrosterone and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J. Clin. Endocrinol. Metab. 1957, 17(9):1051-1062.
4. Orentreich N., Brind J.-L., Vogelman J.-H., Andres R., Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J. Clin. Endocrinol. Metab. 1992, 75(4):1002-1004.
5. Longcope C. Dehydroepiandrosterone metabolism. J. Endocrinol. 1996, 150:S125-S127.
6. Rosenfeld R.-S., Rosenberg B.-J., Fukushima D.-K., Hellman L. 24-hour secretory pattern of dehydroepiandrosterone and dehydroepiandrosterone-sulfate. J. Clin. Endocrinol. Metab. 1975, 40(5):850-855.
7. Labrie F., Belanger A., Cusan L., Gomez J.-L., Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 1997, 82(8):2396-2402.
8. Orentreich N., Brind J.-L., Rizer R.-L., Vogelman J.-H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 1984, 59(3):551-555.
9. Sulcova J., Hill M., Hampl R., Starka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J. Endocrinol. 1997, 154(1):57-62.
10. Parker C.-R., Mixon R.-L., Brissie R.-M., Grizzle W.-E. Aging alters zonation in the adrenal cortex of men. J. Clin. Endocrinol. Metab. 1997, 82(11):3898-3901.
11. Kemnitz J.-W., Roecker E.-B., Haffa A.-L., Pinheiro J., Kurzman I., Ramsey J.-J., MacEwen E.-G. Serum dehydroepiandrosterone sulfate concentrations across the life span of laboratory-housed rhesus monkeys. J. Med. Primatol. 2000, 29(5):330-337.
12. Sapolsky R.-M., Vogelman J.-H., Orentreich N., Altmann J. Senescent decline in serum dehydroepiandrosterone sulfate concentrations in a population of wild baboons. J. Gerontol. 1993, 48(5):B196-B200.
13. Arlt W., Justl H.-G., Callies F., Reincke M., Hubler D., Oettel M., Ernst M., Schulte H.-M., Allolio B. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J. Clin. Endocrinol. Metab. 1998, 83(6):1928-1934.
14. Arlt W., Haas J., Callies F., Reincke M., Hubler D., Oettel M., Ernst M., Schulte H.-M., Allolio B. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J. Clin. Endocrinol. Metab. 1999, 84(6):2170-2176.
15. Svec F., Porter J.-R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. P. Soc. Exp. Biol. Med. 1998, 218(3):174-191.
16. Daynes R.-A., Araneo B.-A., Ershler W.-B., Maloney C., Li G.-Z., Ryu S.-Y. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulphated derivative. J. Immunol. 1993, 150(12):5219-5230.
17. Spencer N.-F.-L., Norton D.-D., Harrison L.-L., Li G.-Z., Daynes R.-A. Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulphated derivative. Exp. Gerontol. 1996, 31(3):393-408.
18. Straub R.-H., Konecna L., Hrach S., Rothe G., Kreutz M., Scholmerich J., Falk W., Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunesenescence. J. Clin. Endocrinol. Metab. 1998, 83(6):2012-2017.
19. Suzuki T., Suzuki N., Daynes R.-A., Engleman E.-G. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin. Immunol. Immunopathol. 1991, 61(2):202-211.
20. Meikle A.-W., Dorchuck R.-W., Araneo B.-A., Stringham J.-D., Evans T.-G., Spruance S.-L., Daynes R.-A. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J. Steroid Biochem. Mol. Biol. 1992, 42(3-4):293-304.
21. Okabe T., Haji M., Takayanagi R., Adachi M., Imasaki K., Kurimoto F., Watanabe T., Nawata H. Up-regulation of high affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J. Clin. Endocrinol. Metab. 1995, 80(10):2993-2996.
22. Catania R.-A., Angele M.-K., Ayala A., Cioffi W.-G., Brand K.-I., Chaudry I.-H. Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine 1999, 11(6):443-450.
23. Zhang Z., Araghi-Niknam M., Liang B., Inserra P., Ardestani S.-K., Jiang S., Chow S., Watson R.-R. Prevention of immune dysfunction and Vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection. Immunology 1999, 96(2):291-297.
24. Ben-Nathan D., Padgett D.-A., Loria R.-M. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J. Med. Microbiol. 1999, 48(5):425-431.
25. Padgett D.-A., Loria R.-M. In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol and androstenetriol. J. Immunol. 1994, 153(4):1544-1552.
26. Moynihan J.-A., Callahan T.-A., Kelley S.-P., Campbell L.-M. Adrenal hormone modulation of type 1 and type 2 cytokine production by spleen cells: dexamethasone and dehydroepiandrosterone suppress interleukin-2, interleukin-4 and interferon-γ production in vitro. Cell. Immunol. 1998, 184(1):58-64.
27. Sakakura Y., Nakagawa Y., Ohzeki T. Differential effect of DHEA on mitogen-induced proliferation of T and B lymphocytes. J. Steroid Biochem. Mol. Biol. 2006, 99(2-3):115-120.
28. Meno-Tetang G.-M.-L., Yi Hon Y., Jusko W.-J. Synergistic interaction between dehydroepiandrosterone and prednisolone in the inhibition of rat lymphocyte proliferation. Immunopharmacol. Immunotoxicol. 1996, 18(3):443-456.
29. Du C., Guan Q., Khalil M.-W., Sriram S. Stimulation of Th2 response by high doses of dehydroepiandrosterone in KLH-primed splenocytes. Exp. Biol. Med. 2001, 226(11):1051-1060.
30. Gordon C.-M., LeBoff M.-S., Glowacki J. Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. Cytokine 2001, 16(5):178-186.
31. McLachlan J.-A., Serkin C.-D., Bakouche O. Dehydroepiandrosterone modulation of lipopolysaccharide stimulated monocyte cytotoxicity. J. Immunol. 1996, 156(1):328-335.
32. Delpedro A.-D., Barjavel M.-J., Mamdouh Z., Bakouche O. Activation of human monocytes by LPS and DHEA. J. Interferon Cytokine Res. 1998, 18(2):125-135.
33. Powell J.-M., Sonnenfeld G. The effects of dehydroepiandrosterone (DHEA) on in vitro spleen cell proliferation and cytokine production. J. Interferon Cytokine Res. 2006, 26(1):34-39.
34. May M., Holmes E., Rogers W., Poth M. Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone. Life Sci. 1990, 46(22):1627-1631.
35. Blauer K.-L., Poth M., Rogers W.-M., Bernton E.-W. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 1991, 129(6):3174-3179.
36. Daynes R.-A., Dudley D.-J., Araneo B.-A. Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur. J. Immunol. 1990, 20(4):793-802.
37. Araneo B., Daynes R. Dehydroepiandrosterone functions as more than an anti-glucocorticoid in preserving immunocompetence after thermal injury. Endocrinology 1995, 136(2):393-401.
38. Loria R.-M., H- Inge T., Cook S.-S., Szakal A.-K., Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone. J. Med. Virol. 1988, 26(3):301-314.
39. Ben-Nathan D., Lustig S., Kobiler D., Danenberg H.-D., Lupu E., Feuerstein G. Dehydroepiandrosterone protects mice inoculated with West Nile virus and exposed to cold stress. J. Med. Virol. 1992, 38(3):159-166.
40. Ben-Nathan D., Lachmi B., Lustig S., Feuerstein G. Protection of dehydroepiandrosterone in mice infected with viral encephalitis. Arch. Virol. 1991, 120(3-4):263-271.
41. Danenberg H.-D., Alpert G., Lustig S., Ben-Nathan D. Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob. Agents Chemother. 1992, 36(10):2275-2279.
42. Cheng G.-F., Tseng J. Regulation of murine interleukin-10 production by dehydroepiandrosterone. J. Interferon Cytokine Res. 2000, 20(5):471-478.
43. van Weerden W.-M., Bierings H.-G., Van Steenbrugge G.-J., De Jong F.-H., Schroder F.-H. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 1992, 50(12):857-861.
44. Dasgupta B., Corkill M., Kirkham B., Gibson T., Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. 1992, 19(1):22-25.
45. Llorente L., Richaud-Patin Y., Fior R., Alcocer-Varela J., Wijdenes J., Fourrier B.-M., Galanaud P., Emilie D. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogrens syndrome and systemic lupus erythematosus. Arthritis Rheum. 1994, 37(11):1647-1655.
46. Du C., Khalil M.-W., Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J. Immunol. 2001, 167(12):7094-7101.
47. Poynter M.-E., Daynes R.-A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signalling and reduces inflammatory cytokine production in aging. J. Biol. Chem. 1998, 273(49):32833-32841.
48. Tomlinson J.-W., Holden N., Hills R.-K., Wheatley K., Clayton R.-N., Bates A.-S., Sheppard M.-C., Stewart P.-M. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357(9254):425-431.
49. Arlt W., Callies F., van Vlijmen J.-C., Koehler I., Reincke M., Bidlingmaier M., Huebler D., Oettel M., Ernst M., Schulte H.-M., Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 1999, 341(14):1013-1020.
50. Solerte S.-B., Fioravanti M., Vignati G., Giustina A., Cravello L., Ferrari E. Dehydroepiandrosterone sulphate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J. Clin. Endocrinol. Metab. 1999, 84(9):3260-3267.
51. Hennebold J.-D., Daynes R.-A. Regulation of macrophage dehydroepiandrosterone sulphate metabolism by inflammatory cytokines. Endocrinology 1994, 135(1):67-75.
52. Butcher S.-K., Chahal H., Nayak L., Sinclair A., Henriquez N.-V., Sapey E., O'Mahony D., Lord J.-M. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J. Leukoc. Biol. 2001, 70(6):881-886.
53. Butcher S.-K., Killampalli V., Lascelles D., Wang K., Alpar E.-K., Lord J.-M. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity. Aging Cell 2005, 4(6):319-324.
54. Aspinall R., Del Giudice G., Effros R.-B., Grubeck-Loebenstein B., Sambhara S. Challenges for vaccination in the elderly. Immun. Ageing. 2007, 4:9.
55. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 1981, 212(4499):1100-1109.
56. Daynes R.-A., Araneo B.-A. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur. J. Immunol. 1990, 19(12):2319-2325.
57. Rundlett S.-E., Miesfeld R.-L. Quantitative differences in androgen and glucocorticoid receptor DNA binding properties contribute to receptor-selective transcriptional regulation. Mol. Cell. Endocrinol. 1995, 109(1):1-10.
58. Mohan P.F., Cleary M.-P. Studies on nuclear binding of dehydroepiandrosterone in hepatocytes. Steroids 1992, 57(5):244-247.
59. Muller C., Cluzeaud F., Pinon G.-M., Oblin M.-E.-R., Morfin R. Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 2004, 92(5):469-476.
60. Turner B.-B. Influence of gonadal steroids on brain corticosteroid receptors: a minireview. Neurochem. Res. 1997, 22(11):1375-1385.
61. Tomlinson J.-W., Walker E.-A., Bujalska I.-J., Draper N., Lavery G.-G., Cooper M.-S., Hewison M., Stewart P.-M. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25(5):831-866.
62. White P.-C., Mune T., Agarwal A.-K. 11ß-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 1997, 18(1):135-156.
63. Apostolova G., Schweizer R.-A.-S., Balazs Z., Kostadinova R.-M., Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2005, 288(5):E957-E964.
64. Balazs Z., Schweizer R.-A.-S., Frey F.-J., Jeanrenaud F.-R., Odermatt A. DHEA induces 11β-HSD2 by acting on CCAAT/enhancer-binding proteins. J. Am. Soc. Nephrol. 2008, 19(1):92-101.
65. Zhang T.-Y., Ding X., Daynes R.-A. The expression of 11β-hydroxysteroid dehydrogenase type 1 by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J. Immunol. 2005, 174(2):879-889.
66. Freeman L., Hewison M., Hughes S.-V., Evans K.-N., Hardie D., Means T.-K., Chakraverty R. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood 2005, 106(6):2042-2049.
67. Thieringer R., Le Grand C.-B., Carbin L., Cai T.-Q., Wong B., Wright S.-D., Hermanowski-Vosatka A. 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 2001, 167(1):30-35.
68. Muller C., Pompon D., Urban P., Morfin R. Inter-conversion of 7α- and 7β-hydroxy-dehydroepiandrosterone by the human 11β-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol. 2006, 99(4-5):215-222.
69. Hennebert O., Chalbot S., Alran S., Morfin R. Dehydroepiandrosterone 7α-hydroxylation in human tissues: possible interference with type 1 11ß-hydroxysteroid dehydrogenase-mediated processes. J. Steroid Biochem. Mol. Biol. 2007, 104(3-5):326-333.
70. Webb S.-J., Geoghegan T.-E., Prough R.-A., Micheal Miller K.-K. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug. Metab. Rev. 2006, 38(1-2):89-116.
71. Kim H., Lee J., Jeong J., Bae S., Lee H., Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem. Biophys. Res. Commun. 1999, 263(1):257-262.
72. Benten W.-P., Lieberherr M., Giese G., Wunderlich F. Estradiol binding to cell surface raises cytosolic free calcium in T cells. FEBS Lett. 1998, 422(3):349-353.
73. i2,3. J. Biol. Chem. 2002, 277(24):21379-21388.
74. Liu D., Dillon J.-S. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004, 69(4):279-289.
75. Liu D., Iruthayanathan M., Homan L.-L., Wang Y., Yang L., Wang Y., Dillon J.-S. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 2008, 149(3):889-898.
76. Loria R.-M., Padgett D.-A. Androstenediol regulates systemic resistance against lethal infections in mice. Arch. Virol. 1992, 127(1-4):103-115.
77. Loria R.-M. Immune up-regulation and tumour apoptosis by androstene steroids. Steroids 2002, 67(12):953-966.
78. Lafaye P., Chmielewski V., Nato F., Mazie J.-C., Morfin R. The 7α-hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens. Biochim. Biophys. Acta 1999, 1472(1-2):222-231.
79. Schmidt M., Kreutz M., Loffler G., Scholmerich J., Straub R.-H. Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J. Endocrinol. 2000, 164(2):161-169.
80. Zhou Z., Shackleton C.-H.-L., Pahwa S., White P.-C., Speiser P.-W. Prominent sex steroid metabolism in human lymphocytes. Mol. Cell. Endocrinol. 1998, 138(1-2):61-69.
81. Hammer F., Drescher D.-G., Schneider S.-B., Quinkler M., Stewart P.-M., Allolio B., Arlt W. Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. J. Clin. Endocrinol. Metab. 2005, 90(11):6283-6289.
82. Araneo B.-A., Woods M.-L., Daynes R.-A. Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant on the immunization of aged mice with recombinant hepatitis B surface antigen. J. Infect. Dis. 1993, 167(4):830-840.
83. Danenberg H.-D., Yehuda A.-B., Rones Z.-Z., Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 1995, 13(15):1445-1448.
84. Garg M., Bondada S. Reversal of age-associated decline in immune response to Pnu-Immune vaccine by supplementation with the steroid hormone dehydroepiandrosterone. Infect. Immun. 1993, 61(5):2238-2241.
85. Williams P.-J., Jones R.-H.-V., Rademacher T.-W. Reduction in the incidence and severity of collagen-induced arthritis in DBA/1 mice using exogenous dehydroepiandrosterone. Arthritis Rheum. 1997, 40(5):907-911.
86. Rontzsch A., Thoss K., Petrow P.-K., Henzgen S., Brauer R. Amelioration of murine antigen-induced arthritis by dehydroepiandrosterone (DHEA). Inflamm. Res. 2004, 53(5):189-198.
87. Angele M.-K., Catania R.-A., Ayala A., Cioffi W.-G., Bland K.-I., Chaudry I.-H. Dehydroepiandrosterone: an inexpensive steroid hormone that decreases the mortality due to sepsis following trauma induced haemorrhage. Arch. Surg. 1998, 133(12):1281-1288.
88. Knoferl M.-W., Angele M.-K., Catania R.-A., Diodato M.-D., Bland K.-I., Chaudry I.-H. Immunomodulatory effects of dehydroepiandrosterone in proestrus female mice after trauma-haemorrhage. J. Appl. Physiol. 2003, 95(2):529-535.
89. Oberbeck R., Nickel E., von-Griensven M., Tschernig T., Wittwer T., Schmitz D., Pape H.-C. The effect of dehydroepiandrosterone on hemorrhage-induced suppression of cellular immune function. Intensive Care Med. 2002, 28(7):963-968.
90. Araneo B.-A., Shelby J., Li G.-Z., Ku W., Daynes R.-A. Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence. Arch. Surg. 1993, 128(3):318-325.
91. Oberbeck R., Dahlweid M., Koch R., Van Griensven M., Emmendorfer A., Tscherne H., Pape H.-C. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit. Care. Med. 2001, 29(2):380-384.
92. Danenberg H.-D., Yehuda A.-B., Rones Z.-Z., Gross D.-J., Friedman G. Dehydroepiandrosterone treatment is not beneficial to the immune response in elderly subjects. J. Clin. Endocrionol. Metab. 1997, 82(9):2911-2914.
93. Yehuda A.-B., Danenberg H.-D., Rones Z.-Z., Gorss D.-J., Friedman G. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Mech. Ageing Dev. 1998, 102(2-3):299-306.
94. Evans T.-G., Judd M.-E., Dowell T., Poe S., Daynes R.-A., Araneo B.-A. The use of oral dehydroepiandrosterone sulphate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine 1996, 14(16):1531-1537.
95. Araneo B., Dowell T., Woods M.-L., Daynes R., Judd M., Evans T. DHEAS as an effective adjuvant in elderly humans. Proof-of-principle studies. Ann. N. Y. Acad. Sci. 1995, 774:232-248.
96. Degelau J., Guay D., Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. J. Am. Geriatr. Soc. 1997, 45(6):747-751.
97. Casson P.-R., Andersen R.-N., Herrod H.-G., Stentz F.-B., Straughn A.-B., Abraham G.-E., Buster J.-E. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am. J. Obstet. Gynecol. 1993, 169(6):1536-1539.
98. Khorram O., Vu L., Yen S.-S. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J. Gerontol. A: Biol. Sci. Med. Sci. 1997, 52(1):M1-7.
99. Kohut M.-L., Thompson J.-R., Campbell J., Brown G.-A., Vukovich M.-D., Jackson D.-A., King D.-S. Ingestion of a dietary supplement containing dehydroepiandrosterone (DHEA) and androstenedione has minimal effect on immune function in middle-aged men. J. Am. Coll. Nutr. 2003, 22(5):363-371.
100. van Vollenhoven R.-F., Engleman E.-G., Mcguire J.-L. An open study of dehydroepiandrosterone in systemic lupus erythmatosus. Arthritis Rheum. 1994, 37(9):1305-1310.
101. Sawalha A.-H., Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr. Rheumatol. Rep. 2008, 10(4):286-291.
102. Chang D.-M., Lan J.-L., Lin H.-Y., Luo S.-F. Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus: a multicenter, randomized, double blind, placebo controlled trial. Arthritis Rheum. 2002, 46(11):2924-2927.
103. Petri M.-A., Mease P.-J., Merrill J.-T., Lahita R.-G., Iannini M.-J., Yocum D.-E., Ginzler E.-M., Katz R.-S., Gluck O.-S., Genovese M.-C., Vollenhoven R.-V., Kalunian K.-C., Manzi S., Greenwald M.-W., Buyon J.-P., Olsen N.-J., Schiff M.-H., Kavanaugh A.-F., Caldwell J.-R., Goldman R.-R., St.Clair E.-W., Goldman A.-L., Egan R.-M., Polisson R.-P., Moder K.-G., Rothfield N.-F., Spencer R.-T., Hobbs K., Fessler B.-J., Calabrese L.-H., Moreland L.-W., Cohen S.-B., Quarles B.-J., Strand V., Gurwith M., Schwartz K.-E. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004, 50(9):2858-2868.
104. Giltay E.-J., van Schaardenburg D., Gooren L.-J.-G., Von Bloomberg B.-M.-E., Fonk J.-C.-M., Touw D.-J., Dijkmans B.-A.-C. Effects of dehydroepiandrosterone administration on disease activity in patients with rheumatoid arthritis. Br. J. Rheumatol. 1998, 37(6):705-706.
105. Andus T., Klebl F., Rogler G., Bregenzer N., Scholmerich J., Straub R.-H. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Ailment. Pharmacol. Ther. 2003, 17(3):409-414.
106. Miller R.-A. The aging immune system: primer and prospectus. Science 1996, 273(5271):70-74.
107. Staino-Coico L., Darzynkiewicz L., Melmed Z., Weksler M.-J. Immunological studies of Aging. IX. Impaired proliferation of T lymphocytes detected in elderly by flow cytometry. Immunology 1994, 132(4):1788-1792.
108. Panda A., Arjona A., Sapey E., Bai F., Fikrig E., Montogomery R.-R., Lord J.-M., Shaw A.-C. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009, 30(7):325-333.
109. Facchini A., Mariani E., Mariani A.-R., Papa S., Vitale M., Manzoli F.-A. Increased number of circulating Leu 11+ (CD16) large granular lymphocytes and decreased NK activity during human aging. Clin. Exp. Immunol. 1987, 68(2):340-347.
110. Setia U., Serventi I., Lorenz P. Factors affecting the use of influenza vaccine in institutionalized elderly. J. Am. Geriatr. Soc. 1985, 33(12):856-858.
111. Govaert T.-M.-E., Sprenger M.-J.-W., Dinant G.-J., Aretz K., Masurel N., Knottnerus J.-A. Immune response to influenza vaccination of elderly people: a randomized double blind placebo-controlled trial. Vaccine 1994, 12(13):1185-1189.
112. Suzuki T., Suzuki N., Engleman E.-G., Mizushima Y., Sakane T. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1995, 99(2):251-255.
113. Hedman M., Nilsson E., de la Torre B. Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. Clin. Exp. Rheumatol. 1992, 10(1):25-30.
114. Straub R.-H., Vogl D., Gross V., Lang B., Scholmerich J., Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am. J. Gastroenterol. 1998, 93(11):2197-2202.
115. Liu C., Zhou H., Qu R., Liu Z. Effects of sex hormones on apoptosis in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Chin. Med. J. (Engl.) 2001, 114(3):291-293.
116. Chang D.-M., Chu S.-J., Chen H.-C., Kuo S.-Y., Lai J.-H. Dehydroepiandrosterone suppresses interleukin-10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. 2004, 63(12):1623-1626.
117. Masi A.-T., Feigenbaum S.-L., Chatterton R.-T. Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Semin. Arthritis Rheum. 1995, 25(1):1-27.
118. Dulos J., Van der Vleuten M.-A.-J., Kavelaars A., Heijnen C.-J., Boots A.-M. CYP7B expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by pro-inflammatory cytokines. Arthritis Rheum. 2005, 52:770-778.
119. Dulos J., Boots A.-H. DHEA metabolism in arthritis: a role for the p450 enzyme Cyp7b at the immune-endocrine crossroad. Ann. N. Y. Acad. Sci. 2006, 1069:401-413.
120. Rose K.-A., Stapleton G., Dott K., Kieny M.-P., Best R., Schwarz M., Russell D.-W., Bjorkhem I., Seckl J., Lathe R. Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehydroepiandrosterone and 7alpha-hydroxy pregnenolone. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(10):4925-4930.
121. Morfin R. Involvement of steroids and cytochromes P(450) species in the triggering of immune defences. J. Steroid Biochem. Mol. Biol. 2002, 80(3):273-290.
122. Dulos J., Verbraak E., Bagchus W.-M., Boots A.-M., Kaptein A. Severity of murine collagen-induced arthritis correlates with increased CYP7B activity: enhancement of dehydroepiandrosterone metabolism by interleukin-1beta. Arthritis. Rheum. 2004, 50(10):3346-3353.
123. Rao M.-S., Subbarao V., Yeldandi A.-V., Reddy J.-K. Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res. 1992, 52(10):2977-2979.
124. Hayashi F., Tamura H., Yamada J., Kasai H., Suga T. Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats. Carcinogenesis 1994, 15(10):2215-2219.
125. Parker L.-N., Levin E.-R., Lifrak E.-T. Evidence for adrenocortical adaptation to severe illness. J. Clin. Endocrinol. Metab. 1985, 60(5):947-952.
126. Papia G., McLellan B.-A., -El- Helou P., Louie M., Rachlis A., Szalai J.-P., Simor A.-E. Infection in hospitalized trauma patients: Incidence, risk factors and complications, J. Trauma-Injury Infect. Crit. Care 1999, 47(5):923-927.
127. Raju R., Bland K.-I., Chaudry I.-H. Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol. Med. 2008, 14(3-4):213-221.
128. Butcher S.-K., Lord J.-M. Stress responses and innate immunity: aging as a contributory factor. Aging Cell 2004, 3(4):151-160.